Analysts Set Perspective Therapeutics, Inc. (NYSE:CATX) Price Target at $15.14

Shares of Perspective Therapeutics, Inc. (NYSE:CATX - Get Free Report) have been assigned an average rating of "Buy" from the nine brokerages that are presently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation, seven have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $15.14.

Several equities analysts recently commented on CATX shares. UBS Group started coverage on Perspective Therapeutics in a research note on Thursday, October 24th. They issued a "buy" rating and a $20.00 price objective on the stock. Royal Bank of Canada reiterated an "outperform" rating and issued a $16.00 price objective on shares of Perspective Therapeutics in a research note on Tuesday, January 14th. Wedbush restated an "outperform" rating and set a $11.00 target price on shares of Perspective Therapeutics in a research report on Friday, January 24th. Oppenheimer dropped their target price on Perspective Therapeutics from $22.00 to $16.00 and set an "outperform" rating on the stock in a research report on Friday, November 22nd. Finally, Cantor Fitzgerald upgraded Perspective Therapeutics to a "strong-buy" rating in a research report on Wednesday, February 5th.

Perspective Therapeutics Price Performance

Perspective Therapeutics stock traded down $0.09 during trading on Thursday, hitting $3.02. The stock had a trading volume of 491,599 shares, compared to its average volume of 988,394. Perspective Therapeutics has a 1 year low of $2.70 and a 1 year high of $19.05. The stock's 50 day moving average is $3.38 and its two-hundred day moving average is $8.75.

Insider Transactions at Perspective Therapeutics

In other news, CEO Johan M. Spoor purchased 8,000 shares of the firm's stock in a transaction dated Wednesday, December 4th. The shares were purchased at an average price of $3.77 per share, with a total value of $30,160.00. Following the completion of the acquisition, the chief executive officer now owns 36,257 shares in the company, valued at $136,688.89. This trade represents a 28.31 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CFO Jonathan Robert Hunt purchased 12,829 shares of the firm's stock in a transaction dated Monday, November 25th. The stock was purchased at an average cost of $3.82 per share, for a total transaction of $49,006.78. Following the acquisition, the chief financial officer now owns 48,800 shares of the company's stock, valued at approximately $186,416. This trade represents a 35.66 % increase in their position. The disclosure for this purchase can be found here. Over the last quarter, insiders have bought 67,570 shares of company stock valued at $256,789. 3.52% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Y Intercept Hong Kong Ltd bought a new position in Perspective Therapeutics in the fourth quarter valued at $33,000. Aigen Investment Management LP bought a new position in Perspective Therapeutics in the fourth quarter valued at $34,000. National Bank of Canada FI increased its stake in Perspective Therapeutics by 549,900.0% in the fourth quarter. National Bank of Canada FI now owns 11,000 shares of the company's stock valued at $35,000 after acquiring an additional 10,998 shares during the last quarter. Vontobel Holding Ltd. bought a new position in Perspective Therapeutics in the fourth quarter valued at $51,000. Finally, Mercer Global Advisors Inc. ADV bought a new position in Perspective Therapeutics in the fourth quarter valued at $51,000. Institutional investors own 54.66% of the company's stock.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.